An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003
Phase of Trial: Phase III
Latest Information Update: 10 Sep 2017
At a glance
- Drugs Abaloparatide (Primary) ; Alendronic acid
- Indications Fracture; Postmenopausal osteoporosis
- Focus Adverse reactions; Registrational
- Acronyms ACTIVExtend
- Sponsors Radius Health Inc.
- 10 Sep 2017 According to a Radius Health media release, results were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2017.
- 10 Aug 2017 Results published in a Radius Health Inc. Media Release.
- 03 Aug 2017 According to a Radius Health media release, additional results from this trial will be presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History